Great ADVFN Post20 Jul 2025 22:11
It's rather funny to read the crap being posted on forums by a few frustrated traders who are discovering they can no longer manipulate the SP. Those historians who enjoy living in the past should perhaps read up on Amazon, Google, Microsoft and numerous other companies that were sure-fire failures.
Many existing Val holders are gradually increasing their positions at these SPs and realistically reducing the volume of shares in free float. Almost every day, buys outnumber sells but all MMs do is increase the spread. A 50% spread would be welcomed by most LT holders, most of whom have absolutely no intention of selling for the foreseeable. By the way, we can expect another TR1 shortly as Stephen W has confirmed adding a few more to his already tidy holding.
With a lucrative signed 401/Ambrose deal already under his belt, Mark E is now finalising his next move. We have several potential sources of RNS we can expect over the coming weeks. Take your pick from SPV's (201 & CLX – both imminent), StingRay – update already overdue, or even further collaborations (all those bio events were not just jollies, despite what some might say). Also, don't discount VAL301. This derives from the 201 stable and still has a decent patent life. This compound, which targets endometriosis, will benefit from the further development of 201 and could well be resurrected.
As regards the fearmongering regarding a summer placing – pure fantasy by a few posters who live in an alternative reality. Val had £1.55m going into January plus Inaphaea are being paid cash for ongoing 401 work. Any SPV announcement (or other good news) will put the SP into "warrant" territory and top up the coffers with anything up to a further £3m+.
Mark E has set up the Advisory Board to explore new market opportunities and manned with an experience trio (ps watch for the expansion into veterinary science). You don't go shopping with an empty wallet. Our CEO expects to have significant funds shortly, without the need for any SH sponsorship, so enabling Val to expand its asset base and start to fulfil its potential.
No-one is denying that, in the past, Val has been a poor investment for many (although a few traders have made a packet). However, we now have a CEO with a significant personal investment, his own hand-picked team, a growing portfolio of assets, the vision to monetise those assets in a much shorter timescale and above all, an understanding of what the biopharma arena wants and the experience needed to deliver.
Sign In
Follow the stocks
